The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Strategic Update

20 Feb 2007 07:00

Embargoed: 0700hrs, 20 February 2007

Akers Biosciences, Inc. Strategic Update

Akers Biosciences, Inc. which develops, manufactures, and supplies rapid, point of care screening and testing products, is pleased to announce that Thomas A. Nicolette has agreed to take an executive position on the board as its new President. Moving Nicolette into an executive role, from his previous non-executive position, marks the transition of the Company from its scientific research and development roots to capitalising on its product portfolio through an emphasis on sales and marketing.

Over the last four years the Company has invested significant resources in the creation and development of platform technologies for rapid testing and screening procedures, and is now in a position to advance the market penetration of its products. Over the last twelve months the Company has made two strategic acquisitions which give it direct access to the US Military and other end users of its BreathScan, BreathAlcohol Check and LegalLimit brands of disposable alcohol testing units. Another important product for the Company is the proprietary PIFA Heparin/PF4 Rapid Assay which is currently being distributed throughout Canada, North America and, imminently, Europe. PIFA H/ PF4 is now in use or evaluation in over 780 hospitals in the US and this number is increasing on a weekly basis, whilst existing hospital customers are moving towards regular re-orders.

In order to facilitate this scale-up in production, as previously announced, the Company is designing a 43,000 sq ft manufacturing facility in Puerto Rico, expected to be on stream by November 2007, affording a substantial reduction in cost of goods manufactured as well as supply chain efficiencies.

Dr Raymond Akers, Chief Executive Officer, commented,

"Tom's appointment as President is extremely beneficial as he will now be able to give his attention, on a full time basis, to working alongside me to extract the full financial potential of our products. Having invested so much of our time and resources in creating our product line, now is the time make the transition to sales and marketing."

Thomas A. Nicolette, President, said,

"Having personally built up a number of technology based companies and progressed them into their commercial phases, I recognise that the Company is poised to enter its commercial phase fully. I am confident that my commercial experience coupled with Dr Akers' intimate understanding of the diagnostic marketplace will put us in a strong position to take advantage of the efforts of the last four years."

Enquiries:Dr. Ray Akers Chief Executive Officer, Akers 001 856 848 8698 Biosciences, Inc.

Thomas Nicolette President, Akers Biosciences, Inc. 001 856 848 8698 Ben Simons Hansard Group 020 7245 1100

Thomas A. Nicolette comes from a blue-chip business background having served as Chairman, President and Chief Executive Officer of several public companies in the USA. The largest, KNOGO Corporation, was a NYSE listed multi-national headquartered on Long Island, NY with subsidiaries, dealers and manufacturing facilities in 32 countries around the world. KNOGO, recognised as the founder of the Electronic Article Surveillance (EAS) anti-shoplifting industry, was sold to Sensormatic Electronics Corporation and is now part of Tyco International, the largest Electronic Security provider in the world.

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring rapid healthcare information directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

AKERS BIOSCIENCES INC
Date   Source Headline
31st Dec 20157:00 amRNSIssue of Equity & Directors' Shareholdings
1st Dec 20157:00 amRNSAkers Biosciences Updates on JV in China
23rd Nov 20157:00 amRNSAppointment of CEO
13th Nov 20157:00 amRNS3rd Quarter Results
12th Nov 201512:00 pmRNSAppointment of Non-Executive Director
11th Nov 20157:00 amRNSNotice of Q3 Results
4th Nov 20157:00 amRNSHIT Test Approved by Chinese FDA
6th Oct 20157:00 amRNSCommercialization of New Breath Tests
30th Sep 20157:00 amRNSDistribution Agreements
14th Sep 20157:00 amRNSLaunch of Breath Ketone test
18th Aug 20157:00 amRNSHalf Yearly Report
14th Aug 20157:00 amRNSNotice of Half Yearly Results
13th Aug 20157:00 amRNSNotice of Half Yearly Results
3rd Aug 20155:29 pmRNSResult of AGM
30th Jun 20152:00 pmRNSAppointment of Non-Executive Director
25th Jun 20155:00 pmRNSAdjournment of Annual General Meeting
16th Jun 20152:30 pmRNSUpdate on Rapid Breath Tests for Wellness Industry
5th Jun 20153:45 pmRNSNotice of AGM and Proposed Board Changes
14th May 20157:00 amRNS1st Quarter Results
12th May 20157:20 amRNSAkers Introduces New Rapid Breath Tests
11th May 20155:50 pmRNSNotice of Q1 Results
11th May 20157:00 amRNSClaim Against ChubeWorkx Guernsey Limited
6th May 20157:01 amRNSResale Agreement
13th Apr 20157:00 amRNSDistribution Agreements
2nd Apr 20157:00 amRNSDistribution Agreement
23rd Mar 201510:52 amRNSFinal Results
19th Mar 20157:00 amRNSNotice of Results
9th Feb 201512:00 pmRNSAkers' Management System Certified to ISO 13485
26th Jan 20157:00 amRNSEuropean Patent Granted
20th Jan 20157:00 amRNSExpansion of US Sales Effort with Key Appointments
9th Jan 20153:03 pmRNSIssue of Equity
9th Jan 20157:00 amRNSIncentive Stock and Award Plan
18th Dec 20147:00 amRNSEuropean Distribution Agreements
10th Dec 20147:00 amRNSOrder to Supply PIFA Products to China
13th Nov 201412:00 pmRNSThird Quarter Results
10th Nov 201412:00 pmRNSNotice of Third Quarter Results
4th Nov 20144:49 pmRNSResult of AGM
23rd Oct 20141:20 pmRNSJV to Market Rapid Diagnostic Tests in China
17th Oct 20143:10 pmRNSNotice of AGM
16th Sep 20145:53 pmRNSAKERS BIOSCIENCES FEATURES ON GLOBAL MEDIA
9th Sep 201412:30 pmRNSSALES CONTRACT FOR RAPID CHOLESTEROL TEST
8th Sep 20147:00 amRNSChange of Adviser
15th Aug 20147:00 amRNSAppointment of Co-chairman
12th Aug 201411:00 amRNSHalf Yearly Report
5th Aug 20147:00 amRNSSenior Managerial Appointment
28th Jul 20147:00 amRNSFeasibility Study For Heart Attack Test
17th Jul 20147:00 amRNSUS Patent - Breath Ketone Detection Device
30th Jun 20147:00 amRNSPosting of Annual Report and Accounts
25th Jun 20147:00 amRNSUS Distribution Agreement
13th Jun 201411:11 amRNSGrant of Options and Directors Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.